Vaxcyte (PCVX) Change in Cash (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Cash data on file, last reported at $86.9 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $86.9 million, up 311.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.9 million (up 67.53% YoY), and the FY2025 annual result was -$213.8 million, down 2184.11% from the prior year.
• Change in Cash grew to $86.9 million in Q1 2026 per PCVX's latest filing, from -$107.1 million in the prior quarter.
• Over five years, Change in Cash peaked at $556.3 million in Q4 2022 and troughed at -$662.3 million in Q4 2024.
• A 5-year average of $11.3 million and a median of $14.3 million in 2023 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2023 and 2024: Change in Cash tumbled 442.14% in 2023, then jumped 3609.86% in 2024.
• A 5-year view of Change in Cash shows it stood at $556.3 million in 2022, then tumbled by 126.55% to -$147.7 million in 2023, then slumped by 348.47% to -$662.3 million in 2024, then jumped by 83.83% to -$107.1 million in 2025, then surged by 181.11% to $86.9 million in 2026.
• Business Quant data shows PCVX's Change in Cash at $86.9 million in Q1 2026, -$107.1 million in Q4 2025, and -$25.5 million in Q3 2025.